Citius Pharmaceuticals (NASDAQ:CTXR) Stock Price Down 0.7% – Here’s What Happened

Posted by George Bondi on Sep 12th, 2026

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR – Get Free Report)’s stock price fell 0.7% during trading on Friday . The stock traded as low as $0.5805 and last traded at $0.5810. 153,785 shares changed hands during mid-day trading, a decline of 75% from the average daily volume of 627,080 shares. The stock had previously closed at $0.5853.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Citius Pharmaceuticals in a research note on Wednesday, June 24th. Citigroup reiterated a “buy” rating on shares of Citius Pharmaceuticals in a report on Wednesday, August 19th. Zacks Research raised Citius Pharmaceuticals to a “hold” rating in a research report on Tuesday, May 19th. Wall Street Zen downgraded Citius Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, June 6th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Citius Pharmaceuticals in a research report on Wednesday, August 19th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $5.00.

View Our Latest Analysis on CTXR

Citius Pharmaceuticals Price Performance

The company has a current ratio of 0.84, a quick ratio of 0.40 and a debt-to-equity ratio of 0.08. The business’s fifty day moving average is $0.59 and its 200 day moving average is $0.67. The company has a market cap of $15.95 million, a P/E ratio of -0.35 and a beta of 1.00.

Citius Pharmaceuticals (NASDAQ:CTXR – Get Free Report) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.02. As a group, sell-side analysts anticipate that Citius Pharmaceuticals, Inc. will post -2.03 EPS for the current year.

Institutional Investors Weigh In On Citius Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. XTX Topco Ltd bought a new position in Citius Pharmaceuticals during the second quarter worth about $32,000. NewEdge Advisors LLC bought a new position in Citius Pharmaceuticals in the 2nd quarter worth approximately $40,000. Asset Advisory Group Inc. purchased a new position in Citius Pharmaceuticals in the 4th quarter valued at approximately $46,000. Heights Capital Management Inc. bought a new stake in Citius Pharmaceuticals during the 4th quarter valued at $622,000. Finally, BlackRock Inc. purchased a new stake in shares of Citius Pharmaceuticals during the second quarter worth $42,000. 16.88% of the stock is owned by hedge funds and other institutional investors.

About Citius Pharmaceuticals

(Get Free Report)

Citius Pharmaceuticals is a clinical‐stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital‐acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter‐related bloodstream infections without catheter removal.